Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (11 quarters reported)
$944M in Q4 2023 → $4.28B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | 8.1% | Added 69% | 6,025,000 | $345M |
| Neurocrine Biosciences Inc | 7.4% | Added 50% | 1,880,000 | $317M |
| Abivax Sa | 7.3% | Added 57% | 2,349,443 | $313M |
| United Therapeutics Corp | 5.5% | Added 480% | 435,000 | $236M |
| Enliven Therapeutics Inc | 4.7% | Added 23% | 4,000,000 | $203M |
| Nurix Therapeutics Inc | 4.6% | Added 24% | 8,050,000 | $195M |
| Bicara Therapeutics Inc | 3.6% | Trimmed 3.2% | 5,250,000 | $156M |
| Taysha Gene Therapies Inc | 3.1% | Added 7.9% | 19,415,000 | $132M |
| Arrowhead Pharmaceuticals Inc | 3.0% | Trimmed 31% | 1,575,000 | $128M |
| Abbott Laboratories | 3.0% | New | 1,400,000 | $127M |
| Zimmer Biomet Holdings Inc | 2.8% | Added 637% | 1,400,000 | $121M |
| Disc Medicine Inc | 2.6% | Added 121% | 1,550,000 | $113M |
| Monte Rosa Therapeutics Inc | 2.6% | Added 28% | 4,600,000 | $111M |
| Insulet Corp | 2.4% | Added 1224% | 670,000 | $102M |
| Ascendis Pharma A/s | 2.3% | New | 375,000 | $100M |
| Astrazeneca PLC | 2.0% | Added 350% | 450,000 | $85.3M |
| Sanofi Sa | 2.0% | Added 43% | 2,000,000 | $85.3M |
| Revolution Medicines Inc | 2.0% | Trimmed 81% | 450,000 | $84.3M |
| Biocryst Pharmaceuticals Inc | 1.9% | Added 18% | 8,300,000 | $83M |
| Dyne Therapeutics Inc | 1.8% | Trimmed 16% | 3,375,000 | $75M |
| Nektar Therapeutics | 1.6% | Added 251% | 1,000,000 | $69.8M |
| Globus Medical Inc | 1.6% | Added 39% | 850,000 | $67.2M |
| Tarsus Pharmaceuticals Inc | 1.5% | Added 425% | 1,050,000 | $66.1M |
| IN Immatics Nv | 1.5% | Unchanged | 6,175,000 | $62.6M |
| Trevi Therapeutics Inc | 1.4% | Added 43% | 3,100,000 | $57.8M |
| Immunocore Holdings PLC | 1.3% | Trimmed 35% | 1,800,000 | $57.2M |
| Repligen Corp | 1.3% | Trimmed 57% | 400,000 | $54.6M |
| Bristol-myers Squibb Co | 1.1% | Trimmed 20% | 800,000 | $46.1M |
| UN Uniqure Nv | 1.0% | Added 160% | 935,000 | $43.1M |
| Xenon Pharmaceuticals Inc | 1.0% | Added 9.4% | 700,000 | $42.3M |
| Bright Minds Biosciences Inc | 0.9% | Added 11% | 545,000 | $38.3M |
| Madrigal Pharmaceuticals Inc | 0.8% | Added 107% | 65,000 | $34.9M |
| Alcon Ag | 0.8% | Trimmed 38% | 500,000 | $33.6M |
| Myriad Genetics Inc | 0.8% | Added 248% | 5,735,000 | $32.7M |
| Rapport Therapeutics Inc | 0.7% | Trimmed 49% | 730,000 | $30.4M |
| Crescent Biopharma Inc | 0.7% | Added 8.7% | 1,630,000 | $29.3M |
| Ge Healthcare Technologies Inc | 0.7% | Added 80% | 450,000 | $28.8M |
| Insmed Inc | 0.6% | New | 250,000 | $26.7M |
| Viking Therapeutics Inc | 0.6% | Trimmed 26% | 680,000 | $26.5M |
| Beta Bionics Inc | 0.6% | Trimmed 28% | 1,600,000 | $25.1M |
| Regeneron Pharmaceuticals Inc | 0.6% | Unchanged | 40,000 | $24.9M |
| Solid Biosciences Inc | 0.5% | Trimmed 57% | 2,160,000 | $21.6M |
| Alto Neuroscience Inc | 0.5% | Trimmed 62% | 785,000 | $20.7M |
| FT First Tracks Biotherapeutics I | 0.5% | New | 1,013,000 | $20.4M |
| Lexeo Therapeutics Inc | 0.5% | Trimmed 3.5% | 4,320,000 | $20.1M |
| Savara Inc | 0.4% | Added 4.6% | 2,720,000 | $16.8M |
| Damora Therapeutics Inc | 0.3% | Trimmed 4.2% | 575,000 | $15M |
| Spyglass Pharma Inc | 0.3% | Added 0.5% | 670,000 | $14.9M |
| Tectonic Therapeutic Inc | 0.3% | Added 30% | 425,000 | $14.6M |
| Avalo Therapeutics Inc | 0.3% | New | 775,000 | $14.3M |
| Evommune Inc | 0.3% | New | 1,000,000 | $13.3M |
| Kailera Therapeutics Inc | 0.3% | New | 575,000 | $12.7M |
| Anteris Technologies Global Co | 0.2% | Trimmed 12% | 1,010,000 | $9.95M |
| Zenas Biopharma Inc | 0.2% | Added 83% | 365,000 | $9.26M |
| Voyager Therapeutics Inc | 0.2% | Trimmed 13% | 2,625,000 | $9.19M |
| Onkure Therapeutics Inc | 0.2% | Trimmed 0.8% | 1,825,699 | $8.33M |
| Surrozen Inc | 0.2% | Trimmed 10% | 304,669 | $7.91M |
| Monopar Therapeutics Inc | 0.2% | Added 16% | 75,727 | $7.01M |
| Zura Bio Ltd | 0.2% | Added 130% | 1,173,956 | $6.93M |
| Olema Pharmaceuticals Inc | 0.1% | Trimmed 2.3% | 418,551 | $5.24M |
Showing top 60 of 68 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | Trimmed | −1,925,000 | −$361M | 2.0% |
| United Therapeutics Corp | Added | +360,000 | +$195M | 5.5% |
| Biomarin Pharmaceutical Inc | Added | +2,450,000 | +$140M | 8.1% |
| Abbott Laboratories | New | +1,400,000 | +$127M | 3.0% |
| Abivax Sa | Added | +849,443 | +$113M | 7.3% |
| Neurocrine Biosciences Inc | Added | +630,000 | +$106M | 7.4% |
| Zimmer Biomet Holdings Inc | Added | +1,210,000 | +$104M | 2.8% |
| Ascendis Pharma A/s | New | +375,000 | +$100M | 2.3% |
| Insulet Corp | Added | +619,399 | +$94.3M | 2.4% |
| Apogee Therapeutics Inc | Exited | −1,100,000 | −$92.6M | — |
Showing the 10 largest of 96 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IQ Invesco Qqq Trust Series 1 | Exited | −350,000 | −$215M | — |
| Revolution Medicines Inc | Added | +2,080,000 | +$202M | 6.5% |
| Arcellx Inc | Exited | −2,925,000 | −$191M | — |
| Terns Pharmaceuticals Inc | Trimmed | −3,500,000 | −$185M | 1.5% |
| Neurocrine Biosciences Inc | New | +1,250,000 | +$165M | 4.6% |
| Repligen Corp | Added | +842,000 | +$99.2M | 3.0% |
| Tyra Biosciences Inc | Trimmed | −2,371,000 | −$90.8M | 0.1% |
| Arrowhead Pharmaceuticals Inc | Added | +1,375,000 | +$86.2M | 4.0% |
| Dexcom Inc | Exited | −1,275,000 | −$84.6M | — |
| Merck & Co Inc | Exited | −775,000 | −$81.6M | — |
Showing the 10 largest of 107 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IQ Invesco Qqq Trust Series 1 | New | +350,000 | +$215M | 7.3% |
| Terns Pharmaceuticals Inc | New | +4,500,000 | +$182M | 6.2% |
| Biomarin Pharmaceutical Inc | Added | +2,170,000 | +$129M | 6.1% |
| Abivax Sa | Added | +900,000 | +$121M | 8.7% |
| Arcellx Inc | Added | +1,675,000 | +$109M | 6.5% |
| Nuvalent Inc | Trimmed | −1,054,000 | −$106M | 0.2% |
| Ascendis Pharma A/s | Trimmed | −425,000 | −$90.6M | 1.3% |
| Merck & Co Inc | New | +775,000 | +$81.6M | 2.8% |
| Amicus Therapeutics Inc | Exited | −9,750,000 | −$76.8M | — |
| Ionis Pharmaceuticals Inc | Exited | −1,075,000 | −$70.3M | — |
Showing the 10 largest of 99 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| UN Uniqure Nv | Trimmed | −3,475,000 | −$203M | 0.6% |
| Cytokinetics Inc | Trimmed | −2,250,000 | −$124M | 1.8% |
| Arcellx Inc | Trimmed | −1,500,000 | −$123M | 4.6% |
| Jazz Pharmaceuticals PLC | Trimmed | −700,000 | −$92.3M | 3.0% |
| Abivax Sa | New | +1,000,000 | +$84.9M | 3.8% |
| Ascendis Pharma A/s | Added | +400,000 | +$79.5M | 5.4% |
| Dianthus Therapeutics Inc | Trimmed | −2,020,000 | −$79.5M | 2.1% |
| Vera Therapeutics Inc | Trimmed | −2,340,000 | −$68M | 1.0% |
| BD Becton Dickinson & Co | Added | +300,000 | +$56.2M | 2.7% |
| Repligen Corp | New | +400,000 | +$53.5M | 2.4% |
Showing the 10 largest of 87 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | New | +1,200,000 | +$127M | 6.7% |
| Insmed Inc | Exited | −1,075,000 | −$82M | — |
| Alcon Ag | New | +525,000 | +$46.3M | 2.4% |
| Revolution Medicines Inc | New | +1,200,000 | +$44.1M | 2.3% |
| Amicus Therapeutics Inc | Added | +7,625,000 | +$43.7M | 3.6% |
| Exact Sciences Corp | New | +700,000 | +$37.2M | 2.0% |
| Ge Healthcare Technologies Inc | Added | +495,870 | +$36.7M | 2.7% |
| Celldex Therapeutics Inc | Added | +1,551,354 | +$31.6M | 1.9% |
| Dianthus Therapeutics Inc | Added | +1,499,931 | +$27.9M | 3.1% |
| Biomarin Pharmaceutical Inc | New | +500,000 | +$27.5M | 1.4% |
Showing the 10 largest of 73 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Added | +1,912,720 | +$125M | 11.2% |
| Jazz Pharmaceuticals PLC | Exited | −975,000 | −$120M | — |
| Merck & Co Inc | Exited | −800,000 | −$79.6M | — |
| Ascendis Pharma A/s | Trimmed | −369,858 | −$57.6M | 1.7% |
| Biomarin Pharmaceutical Inc | Exited | −860,000 | −$56.5M | — |
| Crinetics Pharmaceuticals Inc | New | +1,500,000 | +$50.3M | 3.6% |
| Soleno Therapeutics Inc | Exited | −1,060,000 | −$47.6M | — |
| Scholar Rock Holding Corp | New | +1,300,000 | +$41.8M | 3.0% |
| Ultragenyx Pharmaceutical Inc | Trimmed | −1,000,000 | −$36.2M | 1.3% |
| Sanofi Sa | Exited | −750,000 | −$36.2M | — |
Showing the 10 largest of 76 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Merck & Co Inc | New | +800,000 | +$79.6M | 4.7% |
| Inari Medical Inc | Exited | −1,550,000 | −$63.9M | — |
| Insmed Inc | Trimmed | −700,000 | −$48.3M | 3.7% |
| Nuvalent Inc | New | +600,000 | +$47M | 2.8% |
| Vera Therapeutics Inc | New | +1,075,000 | +$45.5M | 2.7% |
| Cytokinetics Inc | Added | +850,000 | +$40M | 6.6% |
| Ascendis Pharma A/s | Added | +270,000 | +$37.2M | 4.2% |
| Geron Corp | Added | +9,950,000 | +$35.2M | 2.3% |
| Agios Pharmaceuticals Inc | Exited | −760,000 | −$33.8M | — |
| Amicus Therapeutics Inc | New | +3,350,000 | +$31.6M | 1.9% |
Showing the 10 largest of 89 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ascendis Pharma A/s | Trimmed | −500,000 | −$74.7M | 2.8% |
| Jazz Pharmaceuticals PLC | Trimmed | −600,000 | −$66.8M | 7.6% |
| Insmed Inc | Added | +850,000 | +$62.1M | 8.9% |
| Globus Medical Inc | Exited | −900,000 | −$61.6M | — |
| Ultragenyx Pharmaceutical Inc | Trimmed | −1,050,000 | −$58.3M | 3.2% |
| B Beigene Ltd | Exited | −350,000 | −$49.9M | — |
| Inari Medical Inc | Added | +1,200,000 | +$49.5M | 4.8% |
| Exact Sciences Corp | Exited | −925,000 | −$39.1M | — |
| Applied Therapeutics Inc | Trimmed | −4,285,000 | −$36.4M | 0.7% |
| Agios Pharmaceuticals Inc | New | +760,000 | +$33.8M | 2.6% |
Showing the 10 largest of 80 changes.
Loading...
